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Background: In randomized controlled trials (RCTs), colesevelam HCI, added to other anti-diabetic therapy, reduced
hemoglobin A1C by approximately 0.3% to 0.4% over 16- to 26-weeks compared with an increase of approximately
0.1% to 0.2% for placebo, for a placebo-adjusted treatment effect of approximately 0.5%. Evidence on real-world
effectiveness is unknown. This retrospective cohort study examined A1C changes following colesevelam HCL
initiation in patients with diabetes, regardless of concomitant anti-diabetic medication use.
Methods: 2000–2011 GE Centricity electronic medical records data were used to identify patients with type 2
diabetes mellitus (T2DM) aged 18 or older initiating colesevelam HCL. The sample was further restricted to
uncontrolled patients with database activity ≥ 395 days before and after colesevelam HCL initiation, A1C > 7%
during 90 days prior to starting colesevelam HCL, without prior use of bile acid sequestrants, and with at least
one A1C result between 42 to 210 days after initiation. Three overlapping time intervals were created for A1C
measurement, including 16-weeks, 26-weeks, and 52-weeks following therapy initiation. The last observed
A1C lab measurement during each interval was used to define change from baseline. Mean change in A1C
was examined using paired t-tests. Sensitivity analyses considered only patients who remained on
colesevelam HCL through each respective measurement period, as well as the effect of concomitant diabetes
medications.
Results: Of 1,709,393 patients in the GE database with T2DM, 1,747 met inclusion criteria. The cohort was 58%
female, 38% age ≥ 65, and the majority was white. For the 16-week endpoint (N = 1,385), A1C dropped from a mean of
8.22% to 7.75% (mean change −0.47%; P < 0.0001). For the 26- and 52-week endpoints (N = 1,747), A1C dropped from
a mean of 8.25% to 7.81% (mean change −0.44%; P < 0.0001) and 8.25% to 7.79% (mean change −0.46%; P < 0.0001),
respectively. Sensitivity analyses showed that A1C reductions were of similar direction and magnitude for patients who
remained on treatment, and for the subgroups of patients stratified by receipt of concomitant T2DM treatments.
Conclusions: The 0.44% to 0.47% A1C reduction observed in this study was similar to the reduction observed in RCTs,
supporting the real-world effectiveness of colesevelam HCL in reducing A1C.Background
Diabetes is a costly and increasingly prevalent condition
with the number of affected people expected to reach
366 million worldwide by 2030, representing more than
a 2-fold increase from the 171 million people with diag-
nosed diabetes in 2000 [1]. Effective prevention and
treatment of diabetes is becoming more critical than* Correspondence: rah0019@auburn.edu
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reproduction in any medium, provided the orever because the diabetes risk factor of obesity is in-
creasing in prevalence and diabetes is now the seventh
leading cause of death in the U.S. Diabetes is also the
leading cause of kidney failure, non-traumatic lower-
limb amputation, and new cases of blindness among
U.S. adults [2].
Appropriate management of glycemic control in type
2 diabetes mellitus (T2DM) can reduce risks of retin-
opathy, neuropathy, nephropathy, and mortality [3,4].
Given that cardiovascular disease is strongly implicated
in diabetes-related mortality [5], managing otherLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these patients [6-8]. In addition to lifestyle modifica-
tions to address weight, smoking, dietary intake, and
physical activity, controlling diabetes with medications
is an important aspect of preventing diabetes morbid-
ity and mortality [7,9].
In late 2000, colesevelam HCL (Welchol) was ap-
proved by the U.S. Food and Drug Administration
(FDA) as an adjuvant therapy to manage diabetes.
Colesevelam HCL is a second-generation bile acid
sequestrant that, in addition to diet and exercise, can re-
duce low-density lipoprotein cholesterol (LDL) in patients
with hyperlipidemia, and reduce glycated hemoglobin
(A1C) in patients with T2DM. Three randomized trials
demonstrated A1C improvements ranging from 0.50% to
0.54% when patients on oral agents or insulin were
augmented with colesevelam HCL compared with pla-
cebo [10-12]. These randomized controlled trials have
assessed the addition of colesevelam HCL to metfor-
min over 26 weeks (A1C treatment difference −0.54%;
P < 0.001) [10], the addition of colesevelam HCL to
sulfonylurea-based therapy over 26 weeks (A1C treatment
difference −0.54%; P < 0.001) [11], and the addition of
colesevelam HCL to insulin-based therapy over 16 weeks
(A1C treatment difference −0.50%; P < 0.001) [12].
While clinical trials have demonstrated the benefits of
colesevelam HCL for T2DM, less information exists re-
garding real-world, population-based experience. Evi-
dence of real-world effectiveness is important because
evidence of efficacy reflected by randomized controlled
trials may not be generalizable to broader populations
that actually receive treatment in routine clinical prac-
tice [13]. Trial eligibility criteria may exclude or under-
represent important subgroups of patients such as patients
with complex comorbid conditions or certain age groups.
Further, medication adherence in trials is often better than
in the general population, and in fact in colesevelam HCL
trials medication adherence was 93% [10-12], as opposed
to the estimated 50% that exists in the broader population
[14]. These factors might impact estimates of treatment ef-
fectiveness. Therefore, broader evidence is needed to sup-
port the benefits of treatment in practice.
The purpose of this study was to examine changes in
A1C for patients with T2DM receiving colesevelam HCL
using data from a large electronic health record, which
reflects the real-world experience with colesevelam HCL
for lowering A1C in patients with T2DM. Results from
this analysis also demonstrate the extent of concordance
between evidence of clinical efficacy from randomized
trials and real-world effectiveness. This real-world effect-
iveness information is particularly useful given the diver-
sity of patient characteristics, risk factors, and other
treatments used in everyday practice which are not rep-
resented by clinical trial data.Methods
Data and sample
The data and sample were derived from the General
Electric (GE) Centricity Clinical Data Services files from
2000–2011. These files are generated by ambulatory
health care offices that use the GE Centricity electronic
medical record (EMR) and contribute data to the re-
search files. These data represent more than 40 US
states and a variety of ambulatory medical practices, in-
cluding solo practitioners, community clinics, academic
medical centers, and large integrated delivery networks
[15]. Compared with US Census estimates, higher pro-
portions of patients represented in the data reside in
northeastern and mid-western states, while lower pro-
portions reside in southern and western states [16]. The
GE electronic health record (EHR) includes information
on prescribed medications, lists of medications that the
patient reports, patient sociodemographics (age, gender,
race, insurance coverage), diagnoses, procedures, and re-
sults from ordered lab tests. These data represent infor-
mation documented in the electronic medical record for
the purposes of delivering care. The data were stripped
of all 18 unique patient identifiers and did not use any
protected health information that could be linked to hu-
man subjects. This study was exempt from ethics ap-
proval from an institutional review board and informed
consent because, according to the US Department of
Health and Human Services Exemption 4 (CFR 46.101
(b)(4)), the research involved the study of existing data,
and the subjects could not be identified directly or
through identifiers linked to the subjects.
The sample was a retrospective cohort of patients with
T2DM. Patients were included if they had at least one
diagnosis of T2DM in the database (250.x0 or 250.x2).
Initiation of colesevelam HCL was identified as the first
observed prescription or medication list entry in the
dataset, and the date of this prescription defined the
index date. Patients had to have database activity 395 days
before the index date to ensure new colesevelam HCL use.
The sample was further restricted to patients 18 years or
older on the index date who had a baseline A1C > 7%, as
measured by their last A1C value within 90 days prior to
starting colesevelam HCL. Patients who had other bile
acid sequestrants before the baseline A1C measurement
were excluded to isolate the effect of colesevelam HCL
treatment on A1C changes. Patients also had to have at
least one follow-up A1C measurement between 42 to
210 days after initiation. A period of 395 days prior to the
index date was used to define population characteristics
and identify other medication use. The follow-up period
started at index date and continued for 395 days. The
395 day period for pre- and post-index observation was
selected as the maximum period of time that would need
to be observed in order to measure chronic medication
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and this 395 day period allows for 1 year plus a 30 day
grace period for prescription renewals [16].
Outcomes
The primary outcome was change in A1C between initi-
ation of colesevelam HCL (i.e., baseline) and three alter-
native time periods, including 16-weeks (days 42–140),
26-weeks (days 42–210), and 52-weeks (days 42–395)
following initiation. The 16- and 26-week endpoints
were designed to represent comparative endpoints for
clinical trials [10-12]. The 52-week endpoint captured
extended glycemic control from colesevelam HCL treat-
ment beyond that observed in most clinical trials. The
last observed A1C lab measurement during each interval
was used to define the A1C measurement for the corre-
sponding time period.
Covariates
Population and treatment characteristics were assessed as
age, sex, race (i.e., white, black, Asian, other, unknown),
insurance type (i.e., commercial, Medicare, Medicaid, self-
pay, other, unknown), and region (i.e., midwest, northeast,
south, and west). Other treatment use during the baseline
and follow-up period were characterized by major drug
groups for T2DM, including drug class-level indicators
for metformin, insulin, sulfonylureas, thiazolidinediones,
DPP-4 inhibitors, and other miscellaneous diabetes drugs.
Analysis
Descriptive statistics on the final analytic cohort were
examined via means and proportions. Change in A1C
from baseline to 16-weeks, baseline to 26-weeks, and
baseline to 52-weeks was examined via two tailed t-tests.
An a priori alpha of 0.05 was selected for statistical sig-
nificance. The primary analysis considered changes in
A1C from baseline for all eligible patients that started
colesevelam HCL following an intention to treat (ITT)
approach. Unlike claims-based analyses which allow ob-
servation of each prescription fill billed to an insurance
provider, GE data assume continued treatment by a pa-
tient in the absence of a change in prescribing by a pro-
vider as documented in the electronic health record,
making it more difficult to fully capture medication
changes and discontinuation. Given this potential limita-
tion, we felt the ITT analysis appropriate since it did not
restrict patients to continued use of colesevelam HCL
through the entire measurement period but only re-
quired evidence of a prescription at index date.
We also conducted two sensitivity analyses. First, a
sensitivity analysis addressed the potential bias of the
ITT approach by considering only patients who stayed
on colesevelam HCL during the follow-up period, with
no evidence of discontinuation up to 30 days beforetheir last relevant follow-up A1C measurement. These
patients might be considered analogous to patients in a
trial analyzed as “on treatment”, “complete cases”, or
“per protocol” (referred to as “on treatment” from here
forward). Second, a set of sensitivity analyses considered
the effects of other treatments when measuring the
colesevelam HCL effect as there are many other T2DM
medications on the market and our study design allowed
patients to take multiple such medications at any given
time. These analyses divide patients into three strata: 1)
“Monotherapy” initiators, defined as no other T2DM
medication during either baseline or follow-up; 2) “Aug-
ment/Switch”, defined as use of at least one other
T2DM medication during baseline, and colesevelam
HCL was added to the existing treatment or the patient
switched treatment to colesevelam HCL; and 3) “New
Combination”, defined as no other T2DM medication
during baseline but receipt of colesevelam HCL and at
least one other diabetes medication during follow-up.
Initially, the augment and switch groups were defined as
separate groups, but because only 3%-5% (depending on
the stratified analysis) of those who were on other
T2DM medication switched to colesevelam, the two
groups were combined. In defining these groups, a drug
was considered to be used during baseline if it was used
at least once prior to the baseline A1C measurement.
Similarly, a drug was considered to be used during the
outcome assessment interval (i.e., 16-weeks, 26-weeks,
or 52-weeks) if there was no evidence of discontinuation
from the time the drug was started through 30 days be-
fore the last A1C measurement during that interval.
There are 6 stratified analyses because these analyses
were done for both the ITT and the on-treatment ap-
proach, and for all 3 time points (16-weeks, 26-weeks,
and 52-weeks).
Results
Characteristics of the study sample
Of 1,709,393 patients in the GE database with T2DM,
1,747 met inclusion criteria and began treatment with
colesevelam HCL (Figure 1). The cohort was 58% fe-
male, 38% age 65 and older, and the majority (54%) were
white (race information is missing for 34% of patients).
This compares with colesevelam HCL trial populations
that were, on average, 47% female, 59% white, and with
a mean age of 56 years [10-12]. Commercial insurance
(26%) and Medicare (36%) were the most common
forms of coverage, but the payment type for 35% of pa-
tients were unknown. At baseline the mean A1C was
8.25% among all patients prescribed colesevelam HCL.
Prior to beginning colesevelam HCL, 29% of patients
had previously received insulin, 15% had received met-
formin (the only biguanide available), and 13% had re-
ceived sulfonylurea drugs (Table 1).
Patients with type 2 diabetes (T2DM) in
2000-2011 (ICD-9 250.x0 or 250.x2)
N=1709393 
Never initiated
colesevelam HCL 
between 1/1/2001-
12/31/2011
N=1695497 Initiated colesevelam HCL between
1/1/2001-12/31/2011
N=13896 
Had health care utilization in 395 days
before and after start of colesevelam HCL
N=8652 
No health care
utilization in 395 days 
prior to start of 
colesevelam HCL
N=5243 
Had type 1 diabetes or
gestational diabetes
N=115 
No diagnosis of type 1 diabetes or
gestational diabetes
N=8538 
Age > 17
N=8529
Age < 18 or unknown
N=9
No A1C lab value within
90 days of starting 
colesevelam HCL
N=6255 
A1C lab value > 7% within 90 days of starting
colesevelam HCL
N=2274 
No A1C lab value 42-
210 days after starting
colesevelam HCL
N=505
Did not use other bile acid Sequestrants
 during baseline
N=1747 
Final analytic cohort
N=1747
Use of other bile acid
Sequestrants during 
baseline 
N=22 
Had A1C lab value 42 -210 days after starting 
colesevelam HCL
N=1769
Figure 1 Sample selection.
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Intention-to-treat results
Colesevelam HCL initiation corresponded with an A1C re-
duction at 16-, 26-, and 52-weeks for the unadjusted ITT
analysis (Table 2). For the 16-week endpoint (N = 1385),
A1C dropped from a mean of 8.22% to 7.75% (mean
change −0.47%; 95% CI -0.53, -0.41). For the 26- and 52-
week endpoints (N = 1747), A1C dropped from a mean of
8.25% to 7.81% (mean change −0.44%; 95% CI -0.50, -0.38)
and 7.79% (mean change −0.46%; 95% CI −0.52, -0.40),
respectively. All the changes were statistically signifi-
cant (P < 0.0001).
Sensitivity analysis: on-treatment results
Sensitivity analyses considered the potential impact of
the ITT assumption when attributing changes in A1C to
colesevelam HCL. When restricting the analysis to pa-
tients that remained on colesevelam HCL until up to
30 days before their last A1C measurement, we observed
reductions in A1C similar in direction to the ITT ana-
lysis, but of slightly larger magnitude (Table 3). For the
16-week endpoint (N = 838), A1C dropped from a mean
of 8.22% to 7.69% (mean change −0.53%; 95% CI −0.62,-0.44). For the 26-week endpoint (N = 962), A1C dropped
from a mean of 8.25% to 7.71% (mean change −0.54%;
95% CI −0.63, -0.45). For the 52-week endpoint (N = 849),
A1C dropped from a mean of 8.26% to 7.66% (mean
change −0.60%; 95% CI −0.69, -0.51). All of the changes
were statistically significant (P < 0.0001).
Sensitivity analysis that stratify by concomitant T2DM
treatments
Another set of sensitivity analyses considered the impact
of previous or concomitant diabetes treatments when
trying to quantify the colesevelam HCL effect. Since we
used real-world data and our design did not restrict
patients to the types of other drugs allowed that could
also impact A1C measurement, this stratified analysis
attempted to minimize this potential bias. To do this, we
created the “Monotherapy”, “Augment/Switch”, and “New
Combination” treatment cohorts and re-ran the ITT and
on-treatment analysis among each of these population
subgroups. Results are illustrated in Tables 4 and 5.
The A1C changes in each group remained statistically
significant (P < 0.001). The results follow a similar pat-
tern to previous analyses, although the A1C reductions
were larger for the “New Combination” group as op-
posed to the “Monotherapy” and “Augment/Switch”
groups. For example, across the 16-, 26-, and 52-week
endpoints in the ITT analysis (Table 4), the mean reduc-
tion in A1C was between −0.34% to −0.41% for the
newly treated colesevelam HCL monotherapy group, -0
.31% to −0.36% for the colesevelam HCL augment or
switch group, and −0.82% to −0.90% for the newly
treated group that included colesevelam HCL combined
with another medication. Similarly, in the on-treatment
analysis (Table 5), the mean reduction in A1C was
between −0.35% to −0.43% for the newly treated
colesevelam HCL monotherapy group, -0.40% to −0.45% for
the colesevelam HCL augment or switch group, and −1.03%
to −1.18% for the newly treated group that included
colesevelam HCL combined with another medication. Com-
paring the ITT results with the on-treatment results, only
modest differences in the magnitude of the A1C change
were observed. Further, the mean change in A1C was rela-
tively consistent over time for both the ITT and the on-
treatment analyses.
Discussion
In this analysis of real-world use of colesevelam HCL,
we observed a mean reduction in A1C of 0.47% at 16-
weeks, 0.44% at 26-weeks, and 0.46% at 52-weeks
using a conservative ITT approach. These analyses
support the real-world benefits of colesevelam HCL
for managing diabetes and can be compared with clin-
ical trials, where A1C improved by 0.3% to 0.4% over
16- to 26-weeks with colesevelam HCL, as compared
Table 1 Patient characteristics for colesevelam HCL users
Characteristic All T2DM patients
(N = 1747)
Age (n, %)
18-44 years 132 (7.56%)
45-49 years 149 (8.53%)
50-54 years 208 (11.91%)
55-59 years 299 (17.12%)
60-64 years 300 (17.17%)
65-69 years 263 (15.05%)
70-74 years 195 (11.16%)
75-79 years 126 (7.21%)
≥ 80 years 75 (4.29%)
Sex (n, %)
Female 1018 (58.27%)
Male 729 (41.73%)
Race (n, %)
White 938 (53.69%)
Black 160 (9.16%)
Asian 6 (0.34%)
Other 47 (2.69%)
Unknown 596 (34.12%)
Insurance Type (n, %)
Commercial 454 (25.99%)
Medicare 637 (36.46%)
Medicaid 24 (1.37%)
Self-Pay 10 (0.57%)
Other 8 (0.46%)
Unknown 614 (35.15%)
Region (n, %)
Midwest 350 (20.03%)
Northeast 433 (24.79%)
South 847 (48.48%)
West 117 (6.70%)
Baseline A1c Values (mean, SD) 8.25 (1.32)
Prior T2DM Treatments (n, %)
Biguanide 266 (15.23%)
Insulin 506 (28.96%)
Sulfonylurea 231 (13.22%)
Thiazolidinediones 118 (6.75%)
DPP-4 inhibitor 63 (3.61%)
Other Miscellaneous 64 (3.66%)
Number of Prior T2DM Treatments (n, %)
0 808 (46.25%)
1 687 (39.32%)
Table 1 Patient characteristics for colesevelam HCL users
(Continued)
2 204 (11.68%)
3 42 (2.40%)
≥4 6 (0.34%)
Hansen et al. BMC Endocrine Disorders 2013, 13:24 Page 5 of 8
http://www.biomedcentral.com/1472-6823/13/24with an increase of approximately 0.1% to 0.2% for pla-
cebo (placebo-adjusted treatment difference of 0.50% to
0.54%) [10-12].
Our primary analysis used an ITT approach. In the
context of clinical trials, ITT analyses are considered a
preferable approach because randomization is preserved
and results are believed to be more reflective of real-
world practice since not all patients given a treatment
will tolerate it or continue treatment [17]. The ITT ana-
lysis ignores non-adherence, discontinuations, and other
changes in treatment such as switching between diabetes
medications. The last observation carried forward ap-
proach used with ITT handles missing data by carrying
forward the last observed measurement as the planned
endpoint. The ITT approach generally is not favored in
the context of retrospective observational studies be-
cause there is no need to preserve randomization and
data generally are rich enough to measure time-
dependent drug exposure. But, the ITT principle is im-
portant in the context of our real-world data because
our data were prone to problems with limited ability
to measure drug exposure, and outcome measurement
(i.e., A1C) was inconsistent with regard to timing and
consistency. The ITT approach therefore allowed us to
conservatively estimate the treatment effect without
being overly restrictive in our population selection on
the basis of medication use patterns and outcome
measurement. Still, these analyses are subject to biases
that might be introduced by making assumptions
about ongoing medication exposure or carrying for-
ward A1C measures that may be too far removed from
treatment. These biases may be more pronounced in
the 26 and 52 week outcomes which are further re-
moved from baseline observation.
To overcome some of the concerns related to use of
an ITT approach, our sensitivity analyses considered
whether patients continued to take their colesevelam
HCL and the potential effect that other medications
might have on the outcome of interest (i.e., A1C
change). For example, in our “on treatment” sensitivity
analysis, we restricted the analysis to patients that
remained on treatment until at least 30 days before their
last A1C measurement. This assumes ongoing medication
use and we would expect the A1C improvements to be
larger in this analysis as compared with the more conser-
vative ITT analysis. For the on treatment analysis, we ob-
served a mean reduction in A1C of 0.53% at 16-weeks,
Table 2 Mean change in A1C (ITT analyses)
Time
point
LOCF within
day window
Target
day
Actual day N A1C (%)
Mean Baseline mean Post mean Change mean
(95% CI)
Week 16 42 - 140 112 97.0 1385 8.22 7.75 −0.47 (−0.53, -0.41)
Week 26 42 - 210 182 146.2 1747 8.25 7.81 −0.44 (−0.50, -0.38)
Week 52 42 - 395 365 297.6 1747 8.25 7.79 −0.46 (−0.52, -0.40)
P < 0.0001 for all based on t-test of change from baseline to last measure within measurement interval; CI: confidence interval.
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provements were of greater magnitude than the reduc-
tions observed in the ITT analysis, as expected. While this
does not fully address the issue of adherence since the
electronic medical record data is limited in terms of
the insight it can provide regarding medication adher-
ence, the fact that the medication was still active for
these patients and we in turn observed greater A1C
improvements when restricting to active medication
profiles is an important finding.
Relevant RCTs have all added colesevelam HCL to an
existing treatment (e.g., insulin, metformin, or sulfonyl-
urea) and found greater improvements in A1C with the
addition of colesevelam HCL compared with groups that
added placebo to their existing treatment [10-12]. In the
real-world, prior studies have shown that on average pa-
tients with T2DM use 1.6 prescription medications to
manage their diabetes [18]. In our sensitivity analyses
that considered the potential impact of other treatments,
we found the A1C reductions to be largest for the group
that newly initiated colesevelam HCL with another dia-
betes medication. For this group, the A1C reductions
were −0.82% to −0.90% in the ITT analysis and −1.03%
to −1.18% for the on-treatment analysis. These A1C re-
ductions likely reflect both the colesevelam HCL effect
and the beneficial effects of other medication(s), making
it difficult to isolate the effect of colesevelam on A1C re-
ductions. But, for context, this compares with a clinical
trial conducted in patients with early T2DM who had
not previously received treatment [19]. In this 16-week
trial, initial combination therapy with metformin and
colesevelam HCL reduced mean A1C levels by 1.2%
compared with a 0.8% reduction in mean A1C for theTable 3 Mean change in A1C (On treatment analyses)
Time
point
LOCF within
day window
Target
day
Actual day N
Mean
Week 16 42 - 140 112 96.1 8
Week 26 42 - 210 182 142.3 9
Week 52 42 - 395 365 287.7 8
P < 0.0001 for all based on t-test of change from baseline to last measure within mmetformin plus placebo group (P = 0.0035). The mean
difference in A1C reduction between these groups
(−0.4%) is a reflection of the additional benefit of adding
colesevelam HCL. Interestingly, in our subgroup of pa-
tients who newly initiated colesevelam HCL with no
other diabetes medication, we observed an A1C reduc-
tion of 0.41% at 16-weeks in our ITT analysis. Differ-
ences observed in our real-world analysis parallel the
differences reflected by trial data, providing additional
evidence regarding the incremental improvements in
A1C that may be realized with colesevelam HCL.
Several limitations are inherent in the use of observa-
tional data for research and in our analysis. While the
ability to capture laboratory measurements is an import-
ant strength of these data, we were unable to account
for measurements that might have been made outside of
the clinics contributing data to the GE record. Addition-
ally, unlike clinical trials which allow for regular sched-
uled laboratory testing, we had no control over the
timing of laboratory measurements relative to the start
of colesevelam HCL. For measurement of exposure to
colesevelam HCL and other treatments, we relied on the
medication table which includes both patient-reported
medications as well as prescriptions written. Using the
prescription written table may have been a more accur-
ate approach, but then we could have missed use of
colesevelam HCL from other providers not contributing
data to the GE health record. Further, the electronic
medical record does not reflect medication dispensing
(as claims data does) or any aspect of patient adherence,
so we had to assume that if a medication was active and
there was not stop date then the patient was likely still
on the medication. This assumption could overestimateA1C (%)
Baseline mean Post mean Change mean
(95% CI)
38 8.22 7.69 −0.53 (−0.62, -0.44)
62 8.25 7.71 −0.54 (−0.63, -0.45)
49 8.26 7.66 −0.60 (−0.69, -0.51)
easurement interval; CI: confidence interval.
Table 4 Mean ITT changes in A1C (stratified analyses)
Stratum LOCF within
day window
Target
day
Actual day N A1C (%)
Mean Baseline mean Post mean Change mean
(95% CI)
Week 16 42 – 140 112
Monotherapy 97.2 387 7.93 7.52 −0.41 (−0.50, -0.32)
Augment/Switch 97.2 745 8.26 7.90 −0.36 (−0.44, -0.28)
New Combination 96.1 253 8.57 7.69 −0.88 (−1.07, -0.69)
Week 26 42 – 210 182
Monotherapy 145.0 464 7.95 7.61 −0.34 (−0.43, -0.25)
Augment/Switch 146.9 939 8.29 7.97 −0.31 (−0.39, -0.23)
New Combination 146.0 344 8.55 7.65 −0.90 (−1.08, -0.72)
Week 52 42 – 395 365
Monotherapy 285.9 367 7.89 7.52 −0.37 (−0.48, -0.26)
Augment/Switch 300.6 939 8.29 7.96 −0.33 (−0.41, -0.25)
New Combination 300.9 441 8.47 7.65 −0.82 (−0.97, -0.67)
P < 0.001 for all based on t-test of change from baseline to last measure within measurement interval; CI: confidence interval.
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would be most reflected by our “on treatment” sensitiv-
ity analysis. Given the high degree of non-adherence to
diabetes treatments observed in prior studies, our results
are likely conservative and A1C effects could be more
pronounced if adherence could be better accounted for
in our analysis. While our data reflect an electronic
medical record system representing broad US coverage
and many different types of populations and insurance
sources, the clinics using this record system might be
different from other healthcare settings and this could
influence the types of patients represented in this study.
Prior studies suggest that the GE dataset may haveTable 5 Mean on-treatment changes in A1C (stratified analys
Stratum LOCF within
day window
Target
day
Actual day N
Mean
Week 16 42 – 140 112
Monotherapy 96.5 2
Augment/Switch 96.0 4
New Combination 96.1 1
Week 26 42 – 210 182
Monotherapy 141.5 2
Augment/Switch 143.7 5
New Combination 139.3 1
Week 52 42 – 395 365
Monotherapy 283.7 1
Augment/Switch 289.2 4
New Combination 288.3 2
P < 0.0001 for all based on t-test of change from baseline to last measure within mbetter representation of younger patients and females
[20], and we observed a higher representation of females
in our sample (58%) as compared with colesevelam HCL
trials (47%) [10-12]. Finally, since our study focused on
colesevelam HCL users rather than making a compari-
son with non-users or with other treatment groups, we
did not adjust for covariates besides other medication
use in our analysis. Other factors may directly or indir-
ectly influence A1C (e.g., diet, exercise, weight change,
comorbid conditions, etc.), but since we used a pre-post
design and these factors were either not measureable or
believed to be fixed, they were not adjusted in our ana-
lysis. Exploratory analysis of covariance (ANCOVA)es)
A1C (%)
Baseline mean Post mean Change mean (95% CI)
39 7.89 7.51 −0.38 (−0.49, -0.27)
48 8.24 7.80 −0.44 (−0.55, -0.33)
51 8.66 7.63 −1.03 (−1.31, -0.75)
68 7.90 7.55 −0.35 (−0.46, -0.24)
11 8.28 7.87 −0.40 (−0.51, -0.29)
83 8.69 7.51 −1.18 (−1.46, -0.90)
88 7.83 7.40 −0.43 (−0.59, -0.27)
39 8.29 7.84 −0.45 (−0.57, -0.33)
22 8.55 7.52 −1.03 (−1.26, -0.80)
easurement interval; CI: confidence interval.
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across each of the time periods studied. Additional
analyses with larger sample size might explore how
colesevelam HCL-related A1C changes differ among
subgroups.
Conclusions
In this study of real-world patients with T2DM treated
with colesevelam HCL, A1C improved by 0.44% to
0.47%. This reduction in A1C is similar to the A1C im-
provements reported in RCTs, supporting the real-world
effectiveness of colesevelam HCL in managing T2DM.
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